Commonwealth Equity Services LLC Has $1.92 Million Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Commonwealth Equity Services LLC raised its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 0.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 13,941 shares of the company’s stock after buying an additional 84 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Neurocrine Biosciences were worth $1,923,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of NBIX. Vanguard Group Inc. raised its stake in shares of Neurocrine Biosciences by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 9,710,328 shares of the company’s stock valued at $1,279,433,000 after purchasing an additional 150,485 shares in the last quarter. Brown Advisory Inc. raised its stake in shares of Neurocrine Biosciences by 2.2% in the fourth quarter. Brown Advisory Inc. now owns 1,113,413 shares of the company’s stock valued at $146,703,000 after purchasing an additional 23,831 shares in the last quarter. Los Angeles Capital Management LLC raised its stake in shares of Neurocrine Biosciences by 66.0% in the fourth quarter. Los Angeles Capital Management LLC now owns 918,391 shares of the company’s stock valued at $121,007,000 after purchasing an additional 364,986 shares in the last quarter. Vestal Point Capital LP acquired a new position in shares of Neurocrine Biosciences in the fourth quarter valued at $105,408,000. Finally, Jacobs Levy Equity Management Inc. raised its stake in shares of Neurocrine Biosciences by 59.0% in the third quarter. Jacobs Levy Equity Management Inc. now owns 692,374 shares of the company’s stock valued at $77,892,000 after purchasing an additional 256,920 shares in the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Neurocrine Biosciences Stock Performance

NASDAQ:NBIX traded up $0.44 during mid-day trading on Friday, hitting $138.67. The company had a trading volume of 140,466 shares, compared to its average volume of 827,394. Neurocrine Biosciences, Inc. has a fifty-two week low of $93.28 and a fifty-two week high of $148.37. The business’s fifty day moving average is $137.41 and its two-hundred day moving average is $136.09. The firm has a market cap of $13.96 billion, a P/E ratio of 38.08 and a beta of 0.37.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Wednesday, May 1st. The company reported $0.42 earnings per share for the quarter, missing the consensus estimate of $1.04 by ($0.62). Neurocrine Biosciences had a net margin of 18.65% and a return on equity of 17.45%. The company had revenue of $515.30 million during the quarter, compared to analyst estimates of $512.21 million. Equities analysts forecast that Neurocrine Biosciences, Inc. will post 4.22 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. HC Wainwright upped their target price on Neurocrine Biosciences from $150.00 to $160.00 and gave the company a “buy” rating in a research note on Thursday, May 2nd. Wells Fargo & Company upgraded Neurocrine Biosciences from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $140.00 to $170.00 in a research report on Wednesday, April 24th. Wedbush reiterated an “outperform” rating and issued a $152.00 price target on shares of Neurocrine Biosciences in a research report on Wednesday, May 29th. Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a research report on Wednesday, May 1st. Finally, Canaccord Genuity Group upped their price target on Neurocrine Biosciences from $154.00 to $164.00 and gave the company a “buy” rating in a research report on Thursday, May 2nd. Six research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $152.00.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director Shalini Sharp sold 1,106 shares of the stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $141.90, for a total value of $156,941.40. Following the transaction, the director now owns 994 shares of the company’s stock, valued at $141,048.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, Director Shalini Sharp sold 1,106 shares of the firm’s stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $141.90, for a total transaction of $156,941.40. Following the sale, the director now owns 994 shares of the company’s stock, valued at $141,048.60. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Matt Abernethy sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $140.24, for a total value of $2,103,600.00. Following the sale, the chief financial officer now directly owns 31,528 shares in the company, valued at approximately $4,421,486.72. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 98,697 shares of company stock valued at $13,377,515. 4.30% of the stock is currently owned by company insiders.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.